Advertisement

BCG in der Immuntherapie von Tumoren — Eine kurze historische Übersicht

  • P. R. Bock
Conference paper

Zusammenfassung

Bereits Ende des 19. Jahrhunderts wurde beschrieben, daß akute Infektionen oder die Verabreichung von bakteriellen Toxinen manchmal zur Rückbildung von malignen Tumoren führte. Bekannt geworden ist vor allem das „Coley’s“-Toxin des amerikanischen Chirurgen W.E. Coley, der die Heilung eines rezidivierenden Lymphosarkoms nach Erysipelinfektion beobachtete und danach Bakterienextrakte in die adjuvante Karzinomtherapie eingeführt hat [1].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Coley Nauts H, Fowler GA, Bogatka F (1953) A review of the influence of bacterial infection and of bacterial products (Coley’s toxins) on malignant tumors in man. Acta Med Scand 276: 5–14Google Scholar
  2. 2.
    Pearl R (1929) Cancer and tuberculosis. Am J Hypertens 9: 97–159Google Scholar
  3. 3.
    Centanni E, Rezzesi F (1926) Studio sperimentale sul’ antagonismo fra tuberculosi e cancro. Riforma MedT42: 195–200Google Scholar
  4. 4.
    Guérin C (1957) The history of BCG. In: Rosenthal SR (Ed) BCG vaccination against tuberculosis. Little, Brown & Co., Boston, pp 48–53Google Scholar
  5. 5.
    Rosenthal SR (1980) BCG vaccine: tuberculosis-cancer. PSG Publ, Littleton, (Foreword)Google Scholar
  6. 6.
    Mande R (1968) BCG vaccination. Dawsons of Pall Mall, LondonGoogle Scholar
  7. 7.
    Homgren I (1935) La tuberculine et le BCG chez les cancéreux. Schweiz Med Wochenschr 65:1203–1206Google Scholar
  8. 8.
    Old LJ, Clarke DA, Benacerraf B (1959) Effect of Bacillus Calmette- Guérin infection on transplanted tumors in the mouse. Nature 184: 291–292PubMedCrossRefGoogle Scholar
  9. 9.
    Biozzi G, Stiffel C, Halpern BN, Mouton D (1959) Effet de l’inoculation du bacille de Calmette-Guérin sur le développement de la tumeur ascitique d’Ehrlich chez la souris. CR Seances Soc Biol Ses Fil 153: 987–989Google Scholar
  10. 10.
    Halpern, BN, Biozzi G, Stiffel C, Mouton D (1959) Effet de la stimulation du système réticuloendothélial par l’inoculation du bacille de Calmette- Guérin sur le développement de l’éphithélioma atypique T-8 de Guérin chez le rat. CR Seances Soc Biol Ses Fil 153: 919–923Google Scholar
  11. 11.
    Zbar B, Tanaka T (1971) Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis. Science 172: 271–273PubMedCrossRefGoogle Scholar
  12. 12.
    Zbar B, Bernstein ID, Rapp HJ (1971) Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin. J Natl Cancer Inst 46: 831–839PubMedGoogle Scholar
  13. 13.
    Zbar B, Rapp HJ, Ribi EE (1972) Tumor suppression by cell walls of Mycobacterium bovis attached to oil droplets. J Natl Cancer Inst 48: 831–835PubMedGoogle Scholar
  14. 14.
    Zbar B, Bernstein ID, Bartlett GL, Hanna MG Jr, Rapp HJ (1972) Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis. J Natl Cancer Inst 49:119PubMedGoogle Scholar
  15. 15.
    Baldwin RW, Pimm MV (1971) Influence of BCG infection on growth of 3-methyl-cholantrene-induced rat sarcomas. Rev Eur Etud Clin Biol 16: 875–881PubMedGoogle Scholar
  16. 16.
    Bartlett GL, Zbar B (1972) Tumor-specific vaccine containing Mycobacterium bovis and tumor cells: safety and efficacy. J Natl Cancer Inst 48:1709- 1726PubMedGoogle Scholar
  17. 17.
    Bartlett GL, Zbar B, Rapp H J (1972) Suppression of murine tumor growth by immune reaction to the Bacillus Calmette-Guérin strain of Mycobacterium bovis. J Natl Cancer Inst 48: 245–257PubMedGoogle Scholar
  18. 18.
    Inooka S, Ebina T, Tekase Y, et al. (1962) Influence of BCG vaccination on Ehrlich ascites tumor in mice. Kekkaku 37: 503–505Google Scholar
  19. 19.
    Inooka SI (1965) Relation between tumor growth and host resistance. Sei Rep Res Inst Tohoku Univ (Med) 12: 240–266Google Scholar
  20. 20.
    Gillissen G, Nehring G (1969) Das Wachstum von soliden Ehrlich-Ascites- Tumoren bei Mäusen nach Immunisierung mit BCG. Beitr Klin Tuberk 139: 206–210CrossRefGoogle Scholar
  21. 21.
    Lamensans A, Mollier MF, Laurent M (1968) Action du BCG sur l’activité catalasique hépatique chez la souris: relations avec le système réticuloendothélial et la résistance à la leucose greffée AKR. Rev Eur Etud Clin Biol 13: 871–876Google Scholar
  22. 22.
    Amiel JL (1967) Immunothérapie active non spécifique par le B.C.G. de la leucémie virale E male G2 chez des receveurs isogéniques. Rev Eur Etud Clin Biol 12: 912–914Google Scholar
  23. 23.
    Amiel JL, Bérardet M (1969) Essais de traitements de la leucémie E male G2 associant chimiothérapie et immunothérapies actives non spécifique. Rev Eur Etud Clin Biol 14: 685–688Google Scholar
  24. 24.
    Lemonde P, Clode M (1962) Effect of BCG infection on leukemia and polyoma in mice and hamsters. Proc Soc Exp Biol Med 111: 739–742PubMedGoogle Scholar
  25. 25.
    Lemonde P, Dubreuil R, Guindon A, et al. (1971) Stimulating influence of Bacillus Calmette-Guérin on immunity to polyoma tumors and spontaneous leukemia. J Natl Cancer Inst 47:1013–1024PubMedGoogle Scholar
  26. 26.
    Finkelstein JZ, Tille KL, Imagawa DT (1972) Immunoprophylaxis and immunotherapy of leukaemia with B.C.G. Lancet 2: 875–876CrossRefGoogle Scholar
  27. 27.
    Oth D, Burg C (1966) Action d’une inoculation de BCG à des hybrides Fl sur le phénomène de préférence syngénique, présentée par certaines tumeurs isoloques. C R Soc Biol 160:1644–1646Google Scholar
  28. 28.
    Donner M, Oth D, Burg C (1967) Effet du BCG sur l’immunité induite par une tumeur isoloque dans sa souche d’origine et chez des hybrides Fl. C R Soc Biol 161:1661–1664Google Scholar
  29. 29.
    Schwartz E (1973) Effect of Mycobacterium bovis BCG-Praha on the growth of transplanted Daels sarcoma in guinea-pigs. Neoplasma 20:275–386Google Scholar
  30. 30.
    Mathé G, Pouillart P, Lapeyraque F (1969) Active immunotherapy of L 1210 leukaemia applied after the graft of tumour cells. Br J Cancer 23: 814’824PubMedCrossRefGoogle Scholar
  31. 31.
    Mathé G, Pouillart P, Lapeyraque F (1971) Active immunotherapy of mouse RC 19 and E female K 1 leukaemias applied after the intravenous transplantation of the tumour cells. Experientia 27: 446–447PubMedCrossRefGoogle Scholar
  32. 32.
    Baldwin RW, Pimm MV (1971) Influence of BCG infection on growth of 3- methyl-cholanthrene-induced rat sarcomas. Rev Eur Etud Clin Biol 16: 875–881PubMedGoogle Scholar
  33. 33.
    Baldwin RW, Pimm MV (1973) BCG immunotherapy of rat tumors of defined immunogenicity. Natl Cancer Inst Monogr 39: 11–17PubMedGoogle Scholar
  34. 34.
    Parr I (1972) Response of syngeneic murine lymphomata to immunotherapy in relation to the antigenicity of the tumour. Br J Cancer 26:174–182PubMedCrossRefGoogle Scholar
  35. 35.
    Baldwin RW, Pimm MV (1973) BCG immunotherapy of pulmonary growths from intravenously transferred rat tumour cells. Br J Cancer 27: 48–54PubMedCrossRefGoogle Scholar
  36. 36.
    Baldwin RW, Pimm MV (1973) BCG immunotherapy of local subcutaneous growths and postsurgical pulmonary metastases of a transplanted rat epithelioma of spontaneous origin. Int J Cancer 12: 420–427PubMedCrossRefGoogle Scholar
  37. 37.
    Simmons RL, Rios A (1971) Combined use of BCG and neuraminidase in experimental tumor immunotherapy. Surg Forum 22: 99–101PubMedGoogle Scholar
  38. 38.
    Simmons RL, Rios A (1971) Immunotherapy of cancer: immunospecific rejection of tumors in recipients of neuraminidase treated tumor cell plus BCG. Science 174: 591–593PubMedCrossRefGoogle Scholar
  39. 39.
    Rios A, Simmons RL (1972) Comparative effect of Mycobacterium bovis- and neuraminidase-treated tumor cells on the growth of established methyl-cholanthrene fibrosarcomas in syngeneic mice. Cancer Res 32:16–21PubMedGoogle Scholar
  40. 40.
    Simmons RL, Rios A (1972) Immunospecific regression of methylcholan- threne fibrosarcoma using neuraminidase. III. Synergistic effect of BCG and neuraminidase treated tumor cells. Ann Surg 176:188–194PubMedCrossRefGoogle Scholar
  41. 41.
    Simmons RL, Rios A (1973) Comparative and combined effect of BCG and neuramindase in experimental immunotherapy. Natl Cancer Inst Monogr 39: 57–65PubMedGoogle Scholar
  42. 42.
    Mathé G, Halle-Pannenko O, Bourut C (1973) BCG in cancer immunotherapy. II. Results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis and immunotherapy. Natl Cancer Inst Monogr 39: 107–112PubMedGoogle Scholar
  43. 43.
    Sher NA, Pearson JW, Chaparas SD, et al. (1973) Effect of three strains of BCG against a murine leukemia after drug therapie. J Natl Cancer Inst 51: 2001–2003PubMedGoogle Scholar
  44. 44.
    Sparks FC, O’Connell TX, Lee Y-YN (1973) Adjuvant preoperative and postoperative immunochemotherapy for mammary adenocarcinoma in rats. Surg Forum 24:118–121PubMedGoogle Scholar
  45. 45.
    Holmgren I (1935) La tuberculine et le BCG chez les cancéreux. Schweiz Med Wochenschr 65:1203–1206Google Scholar
  46. 46.
    Villasor RP (1965) The clinical use of BCG vaccine in stimulating host resistance to cancer. II Immunochemotherapy in advanced cancer. J Phillip Med Assoc 41: 619–632Google Scholar
  47. 47.
    Kadziev S, Kavaklieva-Dimitrova S (1969) Application du BCG dans le cancer chez l’homme. J Folia Med Neerl 11: 8–14Google Scholar
  48. 48.
    Mathé G, Amiel J, Schwartzenberg L, et al. (1969) Active immunotherapy for acute lymphoblastic leukemia. Lancet 1: 697–699PubMedCrossRefGoogle Scholar
  49. 49.
    Morton DL, Eilber FR, Malmgren RA, et al. (1970) Immunological factors which influence response to immunotherapy in malignant melanoma. Surg 68:158–164Google Scholar
  50. 50.
    Morton DL, Eilber FR, Joseph WL, et al. (1970) Immunological factors in human sarcomas and melanomas: a rational basis for immunotherapy. Ann Surg 172: 740–749PubMedCrossRefGoogle Scholar
  51. 51.
    Morton DL (1971) Immunological studies with human neoplasms. J Reti- culoendothel Soc 10: 137–160Google Scholar
  52. 52.
    Morton DL, Holmes EC, Eilber FR, et al. (1971) Immunological aspects of neoplasia: a rational basis for immunotherapy. Ann Intern Med 74: 587- 604Google Scholar
  53. 53.
    Morton DL (1972) Immunotherapy of human melanomas and sarcomas. Natl Cancer Inst Monogr 35: 375–378PubMedGoogle Scholar
  54. 54.
    Krementz ET, Samuels MS, Wallace JH, et al. (1971) Clinical experiences in immunotherapy of cancer. Surg Gynecol Obstet 133: 209–217PubMedGoogle Scholar
  55. 55.
    Nathanson L (1972) Regression of intradermal malignant melanoma after intralesional injection on Mycobacterium bovis strain BCG. Cancer Chemother Rev 56: 659–665Google Scholar
  56. 56.
    Nathanson L, Clark DA (1973) In vitro assay of cell mediated immunity in BCG therapy of malignant melanoma: a preliminary report. Natl Cancer Inst Monogr 39: 221–224PubMedGoogle Scholar
  57. 57.
    Levy NL, Mahaley MS Jr, Day ED (1972) Serum-mediated blocking of cell- mediated anti-tumor immunity in a melanoma patient: association with BCG immunotherapy and clinical deterioration. Int J Cancer 10: 244–248PubMedCrossRefGoogle Scholar
  58. 58.
    Levy NL (1973) Letter to the editor. Int J Cancer 11: 497CrossRefGoogle Scholar
  59. 59.
    Seigler HF, Shingleton WW, Metzgar RS, et al. (1972) Non-specific and specific immunotherapy in patients with melanoma. Surgery 72:162–174PubMedGoogle Scholar
  60. 60.
    Pinsky C, Hirshaut Y, Oettgen H (1972) Treatment of malignant melanoma by intra-tumoral injection of BCG. Proc Am Assoc Cancer Res 13: 21Google Scholar
  61. 61.
    Pinsky C, Hirshaut Y, Oettgen H (1973) Treatment of malignant melanoma by intratumoral injection of BCG. Natl Cancer Inst Monogr 39: 225–228PubMedGoogle Scholar
  62. 62.
    Sulit H, Chee D, Mastrangelo M, et al. (1972) In vitro assays of cellular and humoral immunity during a clinical trial of immunotherapy in human melanoma. Proc Am Assoc Cancer Res 13: 74Google Scholar
  63. 63.
    Mastrangelo M, Bornstein RS, Sulit H, et al. (1972) Immunotherapy of malignant melanoma. Ann Intern Med 76: 877–878Google Scholar
  64. 64.
    Mastrangelo MJ, Kim YH, Bornstein RS, et al. (1973) Clinico-pathological correlation of BCG induced melanoma regression. Proc Am Assoc Cancer Res 14: 65Google Scholar
  65. 65.
    Bornstein RS, Mastrangelo MJ, Sulit H, et al. (1973) Immunotherapy of melanoma with intralesional BCG. Natl Cancer Inst Monogr 39: 213–220PubMedGoogle Scholar
  66. 66.
    Smith GV, Morse PA Jr, Deraps GD, et al. (1968) Immunotherapy of patients with cancer. Surgery 74: 59–68Google Scholar
  67. 67.
    Minton JP (1973) Mumps virus and BCG vaccine in metastatic melanoma. Arch Surg 106: 503–506PubMedGoogle Scholar
  68. 68.
    Baker MA, Taub RN (1973) BCG in malignant melanoma. Lancet 1:1117–1118PubMedCrossRefGoogle Scholar
  69. 69.
    Sparks FC, Siverstein MJ, Hunt JS, et al. (1973) Complications of BCG immunotherapy in patients with cancer. N Engl J Med 289: 827–830PubMedCrossRefGoogle Scholar
  70. 70.
    Klein E, Holtermann OA, Papermaster B, et al. (1973) Immunologic approaches to various types of cancer with the use of BCG and purified protein derivatives. Natl Cancer Inst Monogr 39: 229–239PubMedGoogle Scholar
  71. 71.
    Klein E, Holtermann OA (1972) Immunotherapeutic approaches to the management of neoplasms. Natl Cancer Inst Monogr 35: 379–402PubMedGoogle Scholar
  72. 72.
    Morton DL, Eilber FR, Malmgren RA, et al. (1970) Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68:158–164PubMedGoogle Scholar
  73. 73.
    Nathanson L (1972) Regression of intradermal malignant melanoma after intralesional injection of Mycobacterium bovis strain BCG. Cancer Chemother Rev 56: 659–665Google Scholar
  74. 74.
    Smith GV, Morse PA Jr, Deraps GD, et al. (1973) Immunotherapy of patients with cancer. Surgery 74: 59–68PubMedGoogle Scholar
  75. 75.
    Bast RC Jr, Zbar B, Borsos T, Rapp HJ (1974) BCG and Cancer (first of two parts). N Engl J Med 290: 1413–1420PubMedCrossRefGoogle Scholar
  76. 76.
    Bast RC Jr, Zbar B, BorsosT, Rapp HJ (1974) BCG and Cancer (second of two parts). N Engl J Med 290:1458–1469PubMedCrossRefGoogle Scholar
  77. 77.
    Baldwin RW, Pimm M (1978) BCG and Cancer. Adv Cancer Res 28: 91–147PubMedCrossRefGoogle Scholar
  78. 78.
    Coe JE, Feldman JD (1966) Extracutaneous delayed hypersensitivity, particularly in the guinea pig bladder. Immunology 10: 127PubMedGoogle Scholar
  79. 79.
    Lamm DL, Reichert DF (1982) Immunotherapy of murine transitional cell carcinoma. J Urol 128:1104–1108PubMedGoogle Scholar
  80. 80.
    Morales A, Ottenhof P, Emerson L (1981) Treatment of residual non-infil- trating bladder cancer with bacillus Calmette-Guerin. J Urol 125: 649PubMedGoogle Scholar
  81. 81.
    Adolphs HD, Thiele J, Kiel H, Steffens L (1978) Induction of transitional cell carcinoma of the urinary bladder in rats by feeding N-[4-(5-nitro-2- furyl)-2-thiazolyl)] formamide. Histological and ultrastructural findings. Urol Res 6: 19PubMedCrossRefGoogle Scholar
  82. 82.
    Adolphs HD, Thiele J, Kiel H (1979) Effect of intralesional and systemic BCG-application or a combined cyclophosphamide/BCG treatment on experimental bladder cancer. Urol Res 7: 71PubMedCrossRefGoogle Scholar
  83. 83.
    Adolphs HD, Thiele J, Kiel H (1981) Inhibition of Experimental Bladder Tumor Induction by Systemic BCG Treatment. Eur Urol 7: 35–38PubMedGoogle Scholar
  84. 84.
    Morales A, Eidinger D, Bruce AW (1976) Intracavitary Bacillus Calmette- Guerin in the treatment of superficial bladder tumors. J Urol 116:18Google Scholar
  85. 85.
    Morales A (1980) Treatment of Carcinoma in situ of the Bladder with BCG. Cancer Immunol Immunother 9: 69–72CrossRefGoogle Scholar
  86. 86.
    Lamm DL (1992) Carcinoma in situ. In: Lamm DL (Ed) The Urologie Clinics of North America. Superficial Bladder Cancer, Vol 19/3. Saunders, Philadelphia, pp 499–508Google Scholar
  87. 87.
    Lamm DL (1992) Long-term results of intravesical therapy for superficial bladder cancer. In: Lamm DL (Ed) The Urologie Clinics of North America. Superficial Bladder Cancer, Vol 19/3. Saunders, Philadelphia, pp 573–580Google Scholar
  88. 88.
    Böhle A, Jocham D (1992) Rezidivprophylaxe des oberflächlichen Urothelkarzinoms und Therapie des Carcinoma in situ der Harnblase mit Bacillus Calmette-Guérin (BCG): eine Übersicht. Zuckschwerdt, MünchenGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • P. R. Bock
    • 1
  1. 1.Institut Mérieux GmbHLeimenDeutschland

Personalised recommendations